Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in JAMA Oncol Retrieve available abstracts of 145 articles: HTML format

Single Articles

September 2024
1. ZHANG L, Li J, Guo L
   Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.
   JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4211.
   PubMed    
   
   
   
2. SORIN M, Prosty C, Spicer JD
   Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer-Reply.
   JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4214.
   PubMed    
   
   
   
3. HU C
   Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.
   JAMA Oncol. 2024 Sep 19. doi: 10.1001/jamaoncol.2024.2905.
   PubMed    
   
   
   
4. SWAMINATH A, Parpia S, Wierzbicki M, Kundapur V, et al
   Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
   JAMA Oncol. 2024 Sep 19:e243089. doi: 10.1001/jamaoncol.2024.3089.
   PubMed     Abstract available
   
   
   August 2024
5. HONG MH, Choi YJ, Ahn HK, Lim SM, et al
   Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
   JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2640.
   PubMed     Abstract available
   
   
   
6. CHENG H
   The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer.
   JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2607.
   PubMed    
   
   
   
7. HATTON JN, Kucera J, Seastedt KP, de Andrade KC, et al
   Characterizing Lung Cancer in Li-Fraumeni Syndrome.
   JAMA Oncol. 2024 Aug 1:e242511. doi: 10.1001/jamaoncol.2024.2511.
   PubMed    
   
   
   
8. LEE JM
   Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung Carcinoma.
   JAMA Oncol. 2024 Aug 1. doi: 10.1001/jamaoncol.2024.2294.
   PubMed    
   
   
   
9. ALTORKI N, Wang X, Damman B, Jones DR, et al
   Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Seconday Analysis of a Randomized Clinical Trial.
   JAMA Oncol. 2024 Aug 1:e242491. doi: 10.1001/jamaoncol.2024.2491.
   PubMed     Abstract available
   
   
   July 2024
10. ROSS HJ, Kozono D, Wang XF, Urbanic JJ, et al
    Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jul 25. doi: 10.1001/jamaoncol.2024.1897.
    PubMed     Abstract available
    
    
    
11. TSAI CH, Chiang PH
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2453.
    PubMed    
    
    
    
12. TAKEMURA N, Lin CC
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer-Reply.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2456.
    PubMed    
    
    
    June 2024
13. CHUN SG, Hu C, Komaki RU, Timmerman RD, et al
    Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Jun 27. doi: 10.1001/jamaoncol.2024.1841.
    PubMed     Abstract available
    
    
    
14. DONG S, Wang Z, Zhang JT, Yan B, et al
    Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Jun 13. doi: 10.1001/jamaoncol.2024.1779.
    PubMed     Abstract available
    
    
    May 2024
15. CHAUNZWA TL, Qian JM, Li Q, Ricciuti B, et al
    Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
    JAMA Oncol. 2024 May 23. doi: 10.1001/jamaoncol.2024.1120.
    PubMed     Abstract available
    
    
    
16. SORIN M, Prosty C, Ghaleb L, Nie K, et al
    Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
    JAMA Oncol. 2024;10:621-633.
    PubMed     Abstract available
    
    
    
17. ROLFO C, Russo A
    The Chemoimmunotherapy Revolution in Resectable NSCLC-The Times They Are A-Changin'.
    JAMA Oncol. 2024;10:569-570.
    PubMed    
    
    
    April 2024
18. NORONHA V, Patil V, Menon N, Shah M, et al
    Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Apr 25. doi: 10.1001/jamaoncol.2024.0584.
    PubMed    
    
    
    
19. RODRIGUES G, Higgins KA, Rimner A, Amini A, et al
    American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 11. doi: 10.1001/jamaoncol.2024.0294.
    PubMed     Abstract available
    
    
    
20. AKAMATSU H
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0231.
    PubMed    
    
    
    
21. TACHIHARA M, Tsujino K
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0234.
    PubMed    
    
    
    
22. SZLOSAREK PW, Creelan BC, Sarkodie T, Nolan L, et al
    Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
    JAMA Oncol. 2024;10:475-483.
    PubMed     Abstract available
    
    
    March 2024
23. ITO K, Suzuki Y, Sakaguchi T, Fujiwara K, et al
    Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0023.
    PubMed     Abstract available
    
    
    
24. TSUKITA Y, Tozuka T, Kushiro K, Hosokawa S, et al
    Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.6277.
    PubMed     Abstract available
    
    
    
25. PALMA DA, Bahig H, Hope A, Harrow S, et al
    Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.7269.
    PubMed     Abstract available
    
    
    
26. KEREKES DM, Frey AE, Prsic EH, Tran TT, et al
    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.
    JAMA Oncol. 2024;10:342-351.
    PubMed     Abstract available
    
    
    January 2024
27. ARRIETA O, Cardenas-Fernandez D, Rodriguez-Mayoral O, Gutierrez-Torres S, et al
    Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5232.
    PubMed     Abstract available
    
    
    
28. LESTER-COLL NH, Park HS
    Stereotactic Body Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer-Is This the Future?
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5856.
    PubMed    
    
    
    
29. WU TC, Luterstein E, Neilsen BK, Goldman JW, et al
    Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.6033.
    PubMed     Abstract available
    
    
    
30. NOGUEIRA LM, Liu Y
    Wildfire Exposure and Lung Cancer Survival-Reply.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6126.
    PubMed    
    
    
    
31. OZAKI A, Murakami M, Leppold C
    Wildfire Exposure and Lung Cancer Survival.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6123.
    PubMed    
    
    
    
32. OKUMA Y, Kubota K, Shimokawa M, Hashimoto K, et al
    First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2024;10:43-51.
    PubMed     Abstract available
    
    
    December 2023
33. WEST HJ, Kim JY
    Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    JAMA Oncol. 2023 Dec 28. doi: 10.1001/jamaoncol.2023.5276.
    PubMed     Abstract available
    
    
    
34. SHIRAISHI Y, Kishimoto J, Sugawara S, Mizutani H, et al
    Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 21. doi: 10.1001/jamaoncol.2023.5258.
    PubMed     Abstract available
    
    
    
35. TEWARI KS, Colombo N, Monk BJ, Dubot C, et al
    Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 14. doi: 10.1001/jamaoncol.2023.5410.
    PubMed     Abstract available
    
    
    
36. TAKEMURA N, Cheung DST, Fong DYT, Lee AWM, et al
    Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 7. doi: 10.1001/jamaoncol.2023.5248.
    PubMed     Abstract available
    
    
    November 2023
37. BONNER SN, Curley R, Love K, Akande T, et al
    Structural Racism and Lung Cancer Risk: A Scoping Review.
    JAMA Oncol. 2023 Nov 30. doi: 10.1001/jamaoncol.2023.4897.
    PubMed     Abstract available
    
    
    
38. WANG VE, Gainor JF
    Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    JAMA Oncol. 2023 Nov 22. doi: 10.1001/jamaoncol.2023.5004.
    PubMed    
    
    
    
39. KIM TW, Bedard PL, LoRusso P, Gordon MS, et al
    Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1574-1582.
    PubMed     Abstract available
    
    
    
40. GENSHEIMER MF, Gee H, Shirato H, Taguchi H, et al
    Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1525-1534.
    PubMed     Abstract available
    
    
    October 2023
41. CHOI E, Ding VY, Luo SJ, Ten Haaf K, et al
    Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4447.
    PubMed     Abstract available
    
    
    
42. SEQUIST LV, Warner ET, Yang CJ
    Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4410.
    PubMed    
    
    
    
43. JEMAL A, Schafer EJ, Sung H, Bandi P, et al
    The Burden of Lung Cancer in Women Compared With Men in the US.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4415.
    PubMed    
    
    
    
44. TAKAHASHI N, Hao Z, Villaruz LC, Zhang J, et al
    Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4025.
    PubMed     Abstract available
    
    
    September 2023
45. ALDEA M, Marinello A, Guyon D, Gazzah A, et al
    Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions.
    JAMA Oncol. 2023 Sep 14. doi: 10.1001/jamaoncol.2023.3625.
    PubMed    
    
    
    
46. TACHIHARA M, Tsujino K, Ishihara T, Hayashi H, et al
    Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3309.
    PubMed     Abstract available
    
    
    
47. GRECO L
    Patients With Brain Metastases Deserve Better-A Hard-Won Perspective.
    JAMA Oncol. 2023;9:1197-1198.
    PubMed    
    
    
    
48. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
    Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1205-1213.
    PubMed     Abstract available
    
    
    August 2023
49. 
    Coding Errors in Study of Eligibility for Lung Cancer Screening.
    JAMA Oncol. 2023 Aug 31. doi: 10.1001/jamaoncol.2023.3792.
    PubMed    
    
    
    
50. POTTER AL, Yang CJ, Palmer JR
    Coding Error in Study Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines.
    JAMA Oncol. 2023 Aug 31. doi: 10.1001/jamaoncol.2023.3505.
    PubMed    
    
    
    
51. LEI J, Zhao J, Gong L, Ni Y, et al
    Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
    JAMA Oncol. 2023 Aug 3. doi: 10.1001/jamaoncol.2023.2751.
    PubMed     Abstract available
    
    
    
52. RICHTERS A, Yildirim H, Booth CM, Vera Badillo FE, et al
    Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review.
    JAMA Oncol. 2023;9:1144-1147.
    PubMed    
    
    
    July 2023
53. ZHANG D, Xi Y, Boffa DJ, Liu Y, et al
    Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival.
    JAMA Oncol. 2023 Jul 27. doi: 10.1001/jamaoncol.2023.2144.
    PubMed     Abstract available
    
    
    June 2023
54. LEE CK, Driscoll E
    Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non-Small Cell Lung Cancer.
    JAMA Oncol. 2023 Jun 22. doi: 10.1001/jamaoncol.2023.1535.
    PubMed    
    
    
    
55. VORUGANTI T, Presley CJ, Gross CP
    Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2023 Jun 22. doi: 10.1001/jamaoncol.2023.1538.
    PubMed    
    
    
    
56. SUN L, Bleiberg B, Hwang WT, Marmarelis ME, et al
    Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2023 Jun 4:e231891. doi: 10.1001/jamaoncol.2023.1891.
    PubMed     Abstract available
    
    
    
57. MAZIERES J, Paik PK, Garassino MC, Le X, et al
    Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2023 Jun 4:e231962. doi: 10.1001/jamaoncol.2023.1962.
    PubMed     Abstract available
    
    
    May 2023
58. PASSARO A, Mok TSK, Attili I, Wu YL, et al
    Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
    JAMA Oncol. 2023 May 11. doi: 10.1001/jamaoncol.2023.0459.
    PubMed     Abstract available
    
    
    April 2023
59. AGGARWAL C, West HJ
    Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data.
    JAMA Oncol. 2023 Apr 13. doi: 10.1001/jamaoncol.2023.0251.
    PubMed    
    
    
    March 2023
60. CARROLL CE, Landrum MB, Wright AA, Keating NL, et al
    Adoption of Innovative Therapies Across Oncology Practices-Evidence From Immunotherapy.
    JAMA Oncol. 2023;9:324-333.
    PubMed     Abstract available
    
    
    
61. RICCIUTI B, Awad MM
    Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment Selection.
    JAMA Oncol. 2023;9:353-354.
    PubMed    
    
    
    February 2023
62. KIM KH, Oh J, Yoon HI
    Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer-Reply.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7878.
    PubMed    
    
    
    
63. WALLS GM, Hanna GG
    Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7875.
    PubMed    
    
    
    
64. SOCINSKI MA, Jotte RM, Cappuzzo F, Nishio M, et al
    Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7711.
    PubMed     Abstract available
    
    
    
65. YEGYA-RAMAN N, Jabbour SK, Feigenberg SJ
    Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7872.
    PubMed    
    
    
    
66. ASLAN V, Yazici O, Ozdemir N
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7586.
    PubMed    
    
    
    
67. RICCIUTI B, Wang X, Awad MM
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7589.
    PubMed    
    
    
    
68. ZHANG X, Zhang L
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7583.
    PubMed    
    
    
    
69. ZHANG X, Ning C, Zhao H
    Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer.
    JAMA Oncol. 2023;9:280.
    PubMed    
    
    
    
70. YOON HH, Shi Q, Ajani JA
    Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.
    JAMA Oncol. 2023;9:280-281.
    PubMed    
    
    
    
71. YAP DWT, Leone AG, Wong NZH, Zhao JJ, et al
    Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    JAMA Oncol. 2023;9:215-224.
    PubMed     Abstract available
    
    
    
72. BAO Y, Zhang H, Bruera E, Portenoy R, et al
    Medical Marijuana Legalization and Opioid- and Pain-Related Outcomes Among Patients Newly Diagnosed With Cancer Receiving Anticancer Treatment.
    JAMA Oncol. 2023;9:206-214.
    PubMed     Abstract available
    
    
    January 2023
73. VORUGANTI T, Soulos PR, Mamtani R, Presley CJ, et al
    Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy.
    JAMA Oncol. 2023 Jan 26. doi: 10.1001/jamaoncol.2022.6901.
    PubMed     Abstract available
    
    
    
74. ZHANG B, Zhong H, Han B
    Neoadjuvant Immunotherapy for Patients With Non-Small Cell Lung Cancer-Is a New Era Coming?
    JAMA Oncol. 2023 Jan 26. doi: 10.1001/jamaoncol.2022.6898.
    PubMed    
    
    
    
75. CHARLOT M, Gray J
    First-line Immunotherapy and Clinically Meaningful Survival Benefits for the Oldest Adults With Lung Cancer.
    JAMA Oncol. 2023 Jan 26. doi: 10.1001/jamaoncol.2022.6867.
    PubMed    
    
    
    
76. YAP TA, Bardia A, Dvorkin M, Galsky MD, et al
    Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:40-50.
    PubMed     Abstract available
    
    
    
77. RAKAEE M, Adib E, Ricciuti B, Sholl LM, et al
    Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
    JAMA Oncol. 2023;9:51-60.
    PubMed     Abstract available
    
    
    December 2022
78. LEE KWC, Li MSC, Gai W, Lau YM, et al
    Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-free DNA in Patients With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2022 Dec 29. doi: 10.1001/jamaoncol.2022.6109.
    PubMed     Abstract available
    
    
    
79. PROVENCIO M, Ortega AL, Coves-Sarto J, Calvo V, et al
    Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2022 Dec 15. doi: 10.1001/jamaoncol.2022.5959.
    PubMed     Abstract available
    
    
    
80. PETTY WJ, Paz-Ares L
    Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2022 Dec 15. doi: 10.1001/jamaoncol.2022.5631.
    PubMed     Abstract available
    
    
    
81. KREBS MG, Malapelle U, Andre F, Paz-Ares L, et al
    Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
    JAMA Oncol. 2022;8:1830-1839.
    PubMed     Abstract available
    
    
    November 2022
82. DESAI AP, Adashek JJ, Reuss JE, West HJ, et al
    Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2022 Nov 17. pii: 2798846. doi: 10.1001/jamaoncol.2022.5389.
    PubMed     Abstract available
    
    
    
83. KATZ MS, Russo GA
    Defining a Therapeutic Ratio for Stereotactic Ablative Radiation Therapy in Oligometastatic Disease-Another Piece of the Puzzle.
    JAMA Oncol. 2022;8:1650-1651.
    PubMed    
    
    
    
84. OLSON R, Jiang W, Liu M, Bergman A, et al
    Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
    JAMA Oncol. 2022;8:1644-1650.
    PubMed     Abstract available
    
    
    
85. STROHBEHN GW, Holleman R, Burns J, Klamerus ML, et al
    Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
    JAMA Oncol. 2022;8:1663-1667.
    PubMed     Abstract available
    
    
    October 2022
86. CANOVA S, Arcangeli S, Cortinovis DL
    A Cast of Shadow on Postoperative Radiotherapy for pIIIA-N2 Non-Small Cell Lung Cancer?
    JAMA Oncol. 2022 Oct 13. pii: 2797485. doi: 10.1001/jamaoncol.2022.4442.
    PubMed    
    
    
    
87. MORIZANE C, Machida N, Honma Y, Okusaka T, et al
    Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:1447-1455.
    PubMed     Abstract available
    
    
    September 2022
88. KIM KH, Oh J, Yang G, Lee J, et al
    Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer.
    JAMA Oncol. 2022 Sep 22. pii: 2796765. doi: 10.1001/jamaoncol.2022.4202.
    PubMed     Abstract available
    
    
    
89. VOLK RJ, Stacey D
    Ensuring High-Quality Shared Decision-making for Lung Cancer Screening.
    JAMA Oncol. 2022 Sep 8. pii: 2796098. doi: 10.1001/jamaoncol.2022.3766.
    PubMed    
    
    
    
90. GERBER DE, Singh H, Larkins E, Ferris A, et al
    A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
    JAMA Oncol. 2022;8:1333-1339.
    PubMed     Abstract available
    
    
    August 2022
91. RICCIUTI B, Wang X, Alessi JV, Rizvi H, et al
    Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    JAMA Oncol. 2022;8:1160-1168.
    PubMed     Abstract available
    
    
    July 2022
92. DESAI A, Velazquez AI, West HJ
    Perioperative Therapy in Early-Stage Lung Cancer.
    JAMA Oncol. 2022 Jul 28. pii: 2794804. doi: 10.1001/jamaoncol.2022.1940.
    PubMed    
    
    
    
93. FASELIS C, Nations JA, Morgan CJ, Antevil J, et al
    Assessment of Lung Cancer Risk Among Smokers for Whom Annual Screening Is Not Recommended.
    JAMA Oncol. 2022 Jul 28. pii: 2794805. doi: 10.1001/jamaoncol.2022.2952.
    PubMed     Abstract available
    
    
    
94. XU J, Liu Z, Bai H, Dong G, et al
    Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2022 Jul 21. pii: 2794634. doi: 10.1001/jamaoncol.2022.2719.
    PubMed     Abstract available
    
    
    April 2022
95. LOUIE AV, Granton PV, Fairchild A, Bezjak A, et al
    Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:1-7.
    PubMed     Abstract available
    
    
    March 2022
96. KEHL KL, Zahrieh D, Yang P, Hillman SL, et al
    Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
    JAMA Oncol. 2022 Mar 17. pii: 2790373. doi: 10.1001/jamaoncol.2022.0039.
    PubMed     Abstract available
    
    
    
97. ARRIETA O, Zatarain-Barron ZL, Turcott JG, Barron F, et al
    Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:477-479.
    PubMed    
    
    
    February 2022
98. ROBBINS HA, Landy R, Ahluwalia JS
    Achieving Equity in Lung Cancer Screening for Black Individuals Requires Innovation to Move Beyond "Equal" Guidelines.
    JAMA Oncol. 2022 Feb 24. pii: 2789385. doi: 10.1001/jamaoncol.2021.7252.
    PubMed    
    
    
    
99. ZHAO B, Ma W
    Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
    JAMA Oncol. 2022 Feb 10. pii: 2789076. doi: 10.1001/jamaoncol.2021.7784.
    PubMed    
    
    
    
100. GIL-SIERRA MD, Del Pilar Briceno-Casado M, Sanchez-Hidalgo M
     Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
     JAMA Oncol. 2022 Feb 10. pii: 2789075. doi: 10.1001/jamaoncol.2021.7787.
     PubMed    
     
     
     
101. GETTINGER S, Redman MW, Herbst RS
     Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply.
     JAMA Oncol. 2022 Feb 10. pii: 2789074. doi: 10.1001/jamaoncol.2021.7790.
     PubMed    
     
     
     
102. HE MM, Lo CH, Wang K, Polychronidis G, et al
     Immune-Mediated Diseases Associated With Cancer Risks.
     JAMA Oncol. 2022;8:209-219.
     PubMed     Abstract available
     
     
     
103. BROWN S, Lavery JA, Shen R, Martin AS, et al
     Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.
     JAMA Oncol. 2022;8:287-291.
     PubMed     Abstract available
     
     
     January 2022
104. ZHANG-VELTEN E, Iyengar P, Timmerman RD
     Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?-Reply.
     JAMA Oncol. 2022 Jan 13. pii: 2788056. doi: 10.1001/jamaoncol.2021.7160.
     PubMed    
     
     
     
105. OHRI N, Werner-Wasik M
     Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?
     JAMA Oncol. 2022 Jan 13. pii: 2788057. doi: 10.1001/jamaoncol.2021.7157.
     PubMed    
     
     
     
106. PU CY, Lusk CM, Neslund-Dudas C, Gadgeel S, et al
     Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
     JAMA Oncol. 2022 Jan 13. pii: 2788055. doi: 10.1001/jamaoncol.2021.6720.
     PubMed     Abstract available
     
     
     
107. NITZ JA, Erkmen CP
     New 2021 USPSTF Lung Cancer Screening Criteria-An Opportunity to Mitigate Racial Disparity.
     JAMA Oncol. 2022 Jan 13. pii: 2788059. doi: 10.1001/jamaoncol.2021.6708.
     PubMed    
     
     
     December 2021
108. NEBHAN CA, Cortellini A, Ma W, Ganta T, et al
     Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
     JAMA Oncol. 2021;7:1856-1861.
     PubMed     Abstract available
     
     
     November 2021
109. POTTER AL, Yang CJ, Woolpert KM, Puttaraju T, et al
     Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines.
     JAMA Oncol. 2021 Nov 24. pii: 2786539. doi: 10.1001/jamaoncol.2021.5790.
     PubMed    
     
     
     
110. KAPOOR A, Prabhash K
     Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
     JAMA Oncol. 2021 Nov 4. pii: 2785696. doi: 10.1001/jamaoncol.2021.5608.
     PubMed    
     
     
     
111. TIAN L, Huang B, Wei LJ
     Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
     JAMA Oncol. 2021 Nov 4. pii: 2785697. doi: 10.1001/jamaoncol.2021.5605.
     PubMed    
     
     
     
112. JABBOUR SK, Keller SM, Reck M
     Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply.
     JAMA Oncol. 2021 Nov 4. pii: 2785695. doi: 10.1001/jamaoncol.2021.5611.
     PubMed    
     
     
     October 2021
113. SINGH H, Beaver JA, Pazdur R
     Immunotherapy for Patients With Small-Cell Lung Cancer-2 Gains, 2 Losses.
     JAMA Oncol. 2021 Oct 28. pii: 2785674. doi: 10.1001/jamaoncol.2021.4956.
     PubMed    
     
     
     
114. MULSHINE JL, Pyenson B
     The Long, Slow Road to Lung Cancer Cure.
     JAMA Oncol. 2021 Oct 21. pii: 2784991. doi: 10.1001/jamaoncol.2021.4711.
     PubMed    
     
     
     
115. GANTI AK, Klein AB, Cotarla I, Seal B, et al
     Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.
     JAMA Oncol. 2021 Oct 21. pii: 2784988. doi: 10.1001/jamaoncol.2021.4932.
     PubMed     Abstract available
     
     
     
116. TOUMAZIS I, de Nijs K, Cao P, Bastani M, et al
     Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
     JAMA Oncol. 2021 Oct 21. pii: 2784987. doi: 10.1001/jamaoncol.2021.4942.
     PubMed     Abstract available
     
     
     
117. ZHOU C, Ramalingam SS, Kim TM, Kim SW, et al
     Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
     JAMA Oncol. 2021 Oct 14:e214761. doi: 10.1001/jamaoncol.2021.4761.
     PubMed     Abstract available
     
     
     
118. AMINI A
     Managing Pulmonary Oligometastatic Disease With Stereotactic Body Radiation Therapy-Moving the Field Forward 1 Organ at a Time.
     JAMA Oncol. 2021;7:1485-1486.
     PubMed    
     
     
     
119. HUANG S, Gao Z, Qiao G
     Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers.
     JAMA Oncol. 2021;7:1580.
     PubMed    
     
     
     
120. WANG J, Leaw SJ, Lu S
     Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers-Reply.
     JAMA Oncol. 2021;7:1580-1581.
     PubMed    
     
     
     September 2021
121. DAGOGO-JACK I
     Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench.
     JAMA Oncol. 2021 Sep 2. pii: 2783495. doi: 10.1001/jamaoncol.2021.3369.
     PubMed    
     
     
     
122. HORN L, Wang Z, Wu G, Poddubskaya E, et al
     Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
     JAMA Oncol. 2021 Sep 2. pii: 2783490. doi: 10.1001/jamaoncol.2021.3523.
     PubMed     Abstract available
     
     
     August 2021
123. KHANDEKAR MJ, Keane FK
     Radiation Dose and Fractionation in Locally Advanced Lung Cancer: A Simple Question With a Complicated Answer.
     JAMA Oncol. 2021 Aug 12. pii: 2783009. doi: 10.1001/jamaoncol.2021.3180.
     PubMed    
     
     
     
124. IYENGAR P, Zhang-Velten E, Court L, Westover K, et al
     Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
     JAMA Oncol. 2021 Aug 12. pii: 2783004. doi: 10.1001/jamaoncol.2021.3186.
     PubMed     Abstract available
     
     
     July 2021
125. EZE C, Belka C, Manapov F
     Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer.
     JAMA Oncol. 2021 Jul 29. pii: 2782115. doi: 10.1001/jamaoncol.2021.2316.
     PubMed    
     
     
     
126. TSAKIRIDIS T, Pond GR, Wright J, Ellis PM, et al
     Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
     JAMA Oncol. 2021 Jul 29. pii: 2782110. doi: 10.1001/jamaoncol.2021.2328.
     PubMed     Abstract available
     
     
     
127. SKINNER H, Hu C, Tsakiridis T, Santana-Davila R, et al
     Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
     JAMA Oncol. 2021 Jul 29. pii: 2782111. doi: 10.1001/jamaoncol.2021.2318.
     PubMed     Abstract available
     
     
     
128. GETTINGER SN, Redman MW, Bazhenova L, Hirsch FR, et al
     Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
     JAMA Oncol. 2021 Jul 15. pii: 2781889. doi: 10.1001/jamaoncol.2021.2209.
     PubMed     Abstract available
     
     
     
129. HUANG H, Feng YL, Liu JH
     Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer-Reply.
     JAMA Oncol. 2021 Jul 15. pii: 2781892. doi: 10.1001/jamaoncol.2021.2113.
     PubMed    
     
     
     
130. SARI SY, Kahvecioglu A, Yildiz F
     Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer.
     JAMA Oncol. 2021 Jul 15. pii: 2781893. doi: 10.1001/jamaoncol.2021.2110.
     PubMed    
     
     
     
131. BARTELS F, Wandrey MM, Aigner A, Stronisch T, et al
     Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer.
     JAMA Oncol. 2021 Jul 1. pii: 2781389. doi: 10.1001/jamaoncol.2021.2049.
     PubMed     Abstract available
     
     
     
132. JACOBSON JO
     Accompanying Patients in the Time of COVID-19.
     JAMA Oncol. 2021;7:971-972.
     PubMed    
     
     
     June 2021
133. HUI Z, Men Y, Hu C, Kang J, et al
     Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
     JAMA Oncol. 2021 Jun 24. pii: 2781087. doi: 10.1001/jamaoncol.2021.1910.
     PubMed     Abstract available
     
     
     
134. JABBOUR SK, Lee KH, Frost N, Breder V, et al
     Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
     JAMA Oncol. 2021 Jun 4. pii: 2780855. doi: 10.1001/jamaoncol.2021.2301.
     PubMed     Abstract available
     
     
     
135. TAKSLER GB, Peterse EFP, Willems I, Ten Haaf K, et al
     Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
     JAMA Oncol. 2021;7:885-894.
     PubMed     Abstract available
     
     
     
136. CHMURA S, Winter KA, Robinson C, Pisansky TM, et al
     Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.
     JAMA Oncol. 2021;7:845-852.
     PubMed     Abstract available
     
     
     May 2021
137. CORBETT K, Sharma A, Pond GR, Brastianos PK, et al
     Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
     JAMA Oncol. 2021 May 20. pii: 2780060. doi: 10.1001/jamaoncol.2021.1359.
     PubMed    
     
     
     
138. DEL PAGGIO JC, Berry JS, Hopman WM, Eisenhauer EA, et al
     Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
     JAMA Oncol. 2021;7:728-734.
     PubMed     Abstract available
     
     
     
139. HOROWITZ DP, Goodman K, Kachnic LA
     Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer-Ready for Prime Time?
     JAMA Oncol. 2021;7:687-688.
     PubMed    
     
     
     
140. STELWAGEN J, de Vries EGE, Walenkamp AME
     Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review.
     JAMA Oncol. 2021;7:759-770.
     PubMed     Abstract available
     
     
     April 2021
141. SUN L, Tan M, Cohen RB, Langer CJ, et al
     Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
     JAMA Oncol. 2021 Apr 15. pii: 2778198. doi: 10.1001/jamaoncol.2021.0546.
     PubMed    
     
     
     
142. KAMRAN SC, Yeap BY, Ulysse CA, Cronin C, et al
     Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
     JAMA Oncol. 2021 Apr 8. pii: 2778095. doi: 10.1001/jamaoncol.2021.0281.
     PubMed     Abstract available
     
     
     
143. SHITARA K, Tabernero J
     Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer-Reply.
     JAMA Oncol. 2021;7:633.
     PubMed    
     
     
     
144. MCCAW ZR, Ludmir EB, Wei LJ
     Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer.
     JAMA Oncol. 2021;7:632-633.
     PubMed    
     
     
     January 2021
145. CHU CY, Er HP, Lin CC
     Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy.
     JAMA Oncol. 2021;7:124-125.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.